| GHS 分類 | This chemical does not meet GHS hazard criteria for 41.4% (1034 of 2499) of reports.WarningH302 (57.2%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2499 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Not Classified |
|---|
| 規制情報 | Chemical: Sulfuric acid, magnesium salt (1:1)Sulfuric acid magnesium salt (1:1) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Sulfuric acid magnesium salt (1:1) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Status: Active Update: 07-04-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/15865Magnesium sulfate anhydrous: Does not have an individual approval but may be used under an appropriate group standard |
|---|
| その他の安全情報 | IMAP assessments - Sulfuric acid, magnesium salt (1:1): Human health tier I assessment |
|---|
| 火災危険 | Not combustible. Gives off irritating or toxic fumes (or gases) in a fire. |
|---|
| 有害性の概要 | No listed effects of short-term or long-term exposure[ICSC] |
|---|
| FDA 要件 | This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.Substance added directly to human food affirmed as generally recognized as safe (GRAS).The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl magnesium sulfate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. Magnesium sulfate is included as a topical acne drug product and an orally administered menstrual drug product.Drug products containing active ingredients offered over-the-counter (OTC) for the treatment of boils. Magnesium sulfate is included in this section. |
|---|
| EPA Safer Chemical | Chemical: Magnesium sulfate, anhydrous |
|---|
| FIFRA 要件 | As the federal pesticide law FIFRA directs, EPA is conducting a comprehensive review of older pesticides to consider their health and environmental effects and make decisions about their future use. Under this pesticide reregistration program, EPA examines health and safety data for pesticide active ingredients initially registered before November 1, 1984, and determines whether they are eligible for reregistration. In addition, all pesticides must meet the new safety standard of the Food Quality Protection Act of 1996. Pesticides for which EPA had not issued Registration Standards prior to the effective date of FIFRA '88 were divided into three lists based upon their potential for human exposure and other factors, with List B containing pesticides of greater concern and List D pesticides of less concern. Magnesium sulfate is found on List D. Case No: 4055Pesticide type: insecticide, herbicideCase Status: No products containing the pesticide are actively registered. Therefore, we are characterizing the case as "cancelled." Under FIFRA, pesticide producers may voluntarily cancel their registered products. EPA also may cancel pesticide registrations if registrants fail to pay required fees or make/meet certain reregistration commitments, or if EPA reaches findings of unreasonable adverse effects.Active ingredient (AI): magnesium sulfateAI Status: The active ingredient is no longer contained in any registered products. Thus, we characterize it as "cancelled."Residues of magnesium sulfate are exempted from the requirement of a tolerance when used as a solid diluent, carrier or safener in accordance with good agricultural practices as inert (or occasionally active) ingredients in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. |
|---|
| Chemical Dangers | Decomposes on heating. This produces toxic and corrosive fumes including sulfur oxides. |
|---|
| Hazard Classes and Categories | Acute Tox. 4 (57.2%)Not Classified |
|---|
| Hazardous Reactivities and Incompatibilities | Potentially explosive reaction when heated with ethoxyethynyl alcohols (e.g., 1-ethoxy-3-methyl-1-butyn-3-ol). |
|---|
| 消火 | In case of fire in the surroundings, use appropriate extinguishing media. |
|---|
| 応急処置措置 | Fresh air, rest.Rinse skin with plenty of water or shower.Rinse with plenty of water (remove contact lenses if easily possible).Rinse mouth. Give one or two glasses of water to drink. |
|---|
| 安全保管 | Dry. |
|---|
| 保管条件 | KEEP WELL CLOSED. /HEPTAHYDRATE/ |
|---|
| 処分方法 | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
|---|
| 漏出処分 | Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Store and dispose of according to local regulations. Wash away remainder with plenty of water. |
|---|
| Eye Prevention | Wear safety spectacles. |
|---|
| Inhalation Risk | A harmful concentration of airborne particles can be reached quickly , especially if powdered. |
|---|
| Minimum Risk Level | 3.5 mmol/L in blood. |
|---|
| Allowable Tolerances | Residues of magnesium sulfate are exempted from the requirement of a tolerance when used as a solid diluent, carrier or safener in accordance with good agricultural practices as inert (or occasionally active) ingredients in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. |
|---|
| Ingestion Prevention | Do not eat, drink, or smoke during work. |
|---|
| Inhalation Prevention | Avoid inhalation of dust. |
|---|
| Treatment | EYES: irrigate opened eyes for several minutes under running water. INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice. SKIN: should be treated immediately by rinsing the affected parts in cold running water for at least 15 minutes, followed by thorough washing with soap and water. If necessary, the person should shower and change contaminated clothing and shoes, and then must seek medical attention. INHALATION: supply fresh air. If required provide artificial respiration. |
|---|
| 相互作用 | ADMIN OF MAGNESIUM SULFATE IN PREECLAMPSIA & ECLAMPSIA POTENTIATES NEUROMUSCULAR BLOCKADE PRODUCED BY D-TUBOCURARINE, DECAMETHONIUM, & SUCCINYLCHOLINE.When barbiturates, opiates, general anesthetics, or other CNS depressants are administered concomitantly with magnesium sulfate, dosage of these agents must be carefully adjusted because of the additive central depressant effects....Magnesium inhibited extracellular calcium entry, intracellular calcium release, cytosolic calcium oscillations, and phasic contractions of myometrial smooth muscle /induced by oxytocin and other uterotonic agonists/....The present in vivo rat study examined the effect of magnesium sulfate to alter the pressor response to norepinephrine (NE) and angiotensin II (A II). Magnesium doses were chosen to approximate those used in treating preeclampsia. NE resulted in a significant rise in mean arterial pressure (delta MAP, 46 +/- 3.7 mmHgp<0.001). A II also resulted in a significant rise in MAP (delta MAP, 23 +/- 3.6 mmHg, p<0.02). Magnesium sulfate alone had no significant effect on MAP but attenuated the pressor response to both NE (delta MAP, 16 +/- 1.5 mmHg) and A II (delta MAP, 12 +/- 2.5 mmHg). After discontinuation of the magnesium sulfate infusion, the control pressor responses to NE and A II were again seen (delta MAP, 39 +/- 3.5 mmHg and delta MAP, 28 +/- 4.2 mmHg, respectively). Although magnesium sulfate is not a primary antihypertensive agent, it may have effects on blood pressure by attenuating the actions of circulating vasoconstrictors.For more Interactions (Complete) data for MAGNESIUM SULFATE (6 total), please visit the HSDB record page. |
|---|
| 健康影響 | May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. Respiratory paralysis occurs at 5 to 6.5 mmol/L. Cardiac conduction is altered at greater than 7.5 mmol/L, and cardiac arrest can be expected when concentrations of magnesium exceed 12.5 mmol/L. |
|---|
| 環境中動態 | AQUATIC FATE: Natural water systems acquire magnesium through weathering reactions, which involve the interaction of water and atmosphere with the earth's crust and subsequent leaching of magnesium compounds into water. The Mg2+ ion is the predominant form of dissolved magnesium. However, some magnesium complexes do form. The magnesium sulfate ion pair complex (MgSO4) is the most significant complex present, representing 2.6% and 11% of the total magnesium content in fresh and sea water, respectively. The concentrations of bicarbonate and carbonate complexes are significant but considerably less than sulfate complexes. Incorporation of magnesium compounds into sediment is an important removal process. For example, a small amount of magnesium is ion exchanged for calcium on clay minerals in ocean sediment. Also small amounts of magnesium carbonate (about 6% of the magnesium supplied by rivers) are deposited with calcite (CaCO3) in seawater. There is significant uptake of magnesium (about 24% of the river input of magnesium) by sediment in which sulfate reduction is taking place(1). The avg Kd value for magnesium sorption on Po River sediments is 1.3 cu m/kg, which suggests that magnesium ions are weakly sorbed on sediments(2). High-temperature alteration of basalts at hydrothermal vents apparently constitute the most important sink for magnesium in seawater(1). |
|---|
| 有害作用 | When giving magnesium sulfate, there are minimal side effects with standard therapeutic doses, but magnesium sulfate has a broad therapeutic index. Patients most commonly complain of minor facial flushing and warmth with the administrationhowever, symptoms typically resolve spontaneously. In patients with neuromuscular disease, such as in myasthenia gravis, the neuromuscular function may worsen at lower concentrations of medication. If given rapidly or in high doses, patients may experience transient hypotension due to smooth muscle inhibition causing a vasodilatory effect that will resolve. If the patient is on a continuous magnesium sulfate infusion, serum levels must be accounted for as symptoms related to hypermagnesemia may become clinically evident. At supratherapeutic serum concentrations, absent reflexes, abnormal cardiac conduction, and muscle weakness may occur. |
|---|
| 暴露経路 | The substance can be absorbed into the body by inhalation of its aerosol and by ingestion.Parenteral(intravenous, intramuscular) oral. |
|---|
| 毒性の概要 | Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.orgIf patients exhibit signs and symptoms of hypermagnesemia, the recommendation is to discontinue magnesium sulfate products immediately. If the patient consumed magnesium sulfate orally, then the use of magnesium-free enemas or cathartics can be useful in removing excess magnesium from the GI tract. Patients should receive parenteral doses of calcium gluconate to help alleviate symptoms, but continued doses may be necessary as the calcium provides temporary improvement. IV hydration should also occur if clinically appropriate. In patients with severe renal disease, then hemodialysis should be considered.Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca<sup>2+</sup> influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle. |
|---|
| Signs and Symptoms | Cough.Redness.Abdominal pain. Diarrhoea. Vomiting.Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression. |
|---|
| Natural Pollution Sources | OCCURS IN NATURE AS THE MINERAL EPSOMITE. /HEPTAHYDRATE/MONOHYDRATE OCCURS IN NATURE AS MINERAL KIESERITE. /MONOHYDRATE/ |
|---|
| Human Toxicity Excerpts | /HUMAN EXPOSURE STUDIES/ Human systemic effects: heart changes, cyanosis, flaccid paralysis with appropriate anesthesia. |
|---|
| Artificial Pollution Sources | The production and use of magnesium compounds as refractories, as chemical intermediates, and in construction materials(1,2) result in their release to the environment through various waste streams(SRC). The production and use of magnesium compounds in environmental applications and in agriculture(1,2) results in their direct release to the environment(SRC). About 69% of the magnesium compounds used in the United States were used for refractories (e.g., olivine)(1). The remaining 31% of magnesium compounds were used in agriculture as fertilizer or animal feed (e.g, magnesium oxide, magnesium sulfate), as chemical intermediates (e.g., magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium oxide) , construction materials (e.g., magnesium oxide), environmental (e.g., magnesium oxide, magnesium hydroxide), and industrial applications (e.g., magnesium oxide)(1,2). Other uses include road dust and ice control (e.g., magnesium chloride), pulp and paper applications (e.g.,magnesium sulfate), pharmaceuticals (e.g., magnesium sulfate, magnesium carbonate, magnesium oxide), and cosmetics (e.g., magnesium carbonate)(1,2). |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
